Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.86, $0.12 better than the analyst estimate of $0.74. Revenue for the quarter came in at $385.19 million versus the consensus estimate of $380.6 million.

GUIDANCE
Full year 2022 adjusted EPS guidance is being raised to a range of $3.29 to $3.33, an increase of $0.15 at the mid-point compared to the Company’s August guidance.

For the fourth quarter 2022, the Company expects reported revenues in the range of $391 million to $403 million, representing reported growth of -3.5% to -0.6% and organic growth of 1.3% to 4.3%. Adjusted earnings per diluted share is expected to be in a range of $0.87 to $0.91.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.